|
業務類別
|
Biotechnology |
|
業務概覽
|
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. |
| 公司地址
| 465 North Halstead Street, Suite 200, Pasadena, CA, USA, 91107 |
| 電話號碼
| +1 626 305-5900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.xencor.com |
| 員工數量
| 260 |
| Mr. John R. Desjarlais, PhD |
Executive Vice President, Research and Chief Scientific Officer |
美元 534.50K |
23/04/2025 |
| Dr. Bassil I. Dahiyat, PhD. |
Director, President and Chief Executive Officer |
美元 721.20K |
25/02/2026 |
| Ms. Celia E. Eckert |
Senior Vice President, General Counsel and Corporate Secretary |
美元 475.00K |
23/04/2025 |
| Mr. Bart Jan Cornelissen |
Senior Vice President, Principal Accounting Officer and Chief Financial Officer |
美元 338.18K |
25/02/2026 |
|
|
| Dr. A. Bruce Montgomery, M.D. |
Lead Independent Director |
25/02/2026 |
| Dr. Kevin C. Gorman,PhD |
Independent Director |
25/02/2026 |
| Mr. Richard J. Ranieri |
Independent Director |
25/02/2026 |
| Mr. Kurt A. Gustafson |
Independent Director |
25/02/2026 |
| Dr. Barbara Klencke, M.D. |
Independent Director |
25/02/2026 |
| Dr. Raymond J. Deshaies, PhD |
Director |
25/02/2026 |
| Mr. Todd E. Simpson |
Director |
25/02/2026 |
| Dr. Bassil I. Dahiyat, PhD. |
Director, President and Chief Executive Officer |
25/02/2026 |
| Dr. Ellen G. Feigal, M.D. |
Independent Director |
25/02/2026 |
|
|
|
|
